Friday, May 13, 2022, New Orleans, Louisiana, 8:00 AM – 10:00 AM Central Time (9:00 AM – 11:00 AM Eastern Time)

Cases from the Community: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Prostate Cancer

Part 1 of a 2-Part CME Satellite Symposium Series in Conjunction with the American Urological Association (AUA) 2022 Annual Meeting

Location
New Orleans Ernest N Morial Convention Center
900 Convention Center Blvd
New Orleans, LA 70130
Phone: (504) 582-3000

Program Schedule — Central Time
7:30 AM – 8:00 AM — Registration
8:00 AM – 10:00 AM — Breakfast Meeting

Meeting Room
Rooms 265-268 (Second Floor)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in New Orleans, preregistration is required as seating is limited.  
 
Faculty
Raoul S Concepcion, MD
Chief Science Officer
US Urology Partners
Nashville, Tennessee

Fred Saad, MD
Professor and Chief of Urology
Director of GU Oncology
Raymond Garneau Chair in Prostate Cancer
University of Montreal Hospital Center (CHUM)
Director, Prostate Cancer Research
Montreal Cancer Institute/CRCHUM
Montréal, Québec, Canada


Matthew R Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Moderator
Emmanuel S Antonarakis, MD
Clark Endowed Professor of Medicine
Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota


This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck, and Pfizer Inc.
Program Schedule — Central Time
7:30 AM – 8:00 AM — Registration
8:00 AM – 10:00 AM — Educational Breakfast Meeting

MODULE 1: Management Approaches for Nonmetastatic Prostate Cancer — Dr Concepcion

  • Major efficacy and safety findings with the oral LHRH antagonist relugolix in men with advanced prostate cancer; patient selection and optimal integration into current clinical practice
  • Key efficacy and safety findings from the STAMPEDE trial assessing the addition of abiraterone and prednisolone with or without enzalutamide to androgen deprivation therapy (ADT) for men with high-risk nonmetastatic prostate cancer; implications for routine practice
  • Ongoing Phase III trials evaluating secondary hormonal therapy for high-risk localized or locally advanced prostate cancer
  • Pharmacologic and pharmacodynamic similarities and differences between apalutamide, enzalutamide and darolutamide
  • Long-term efficacy outcomes, including metastasis-free and overall survival, with apalutamide, enzalutamide and darolutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC)
  • Spectrum, frequency and severity of toxicities associated with enzalutamide, apalutamide and darolutamide
  • Clinical, biologic and practical factors guiding selection among enzalutamide, apalutamide and darolutamide for nmCRPC

MODULE 2: Role of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Dr Smith

  • Rationale for treatment intensification in patients with mHSPC; historical outcomes observed with ADT alone in this population and guideline-endorsed adjunctive strategies
  • Long-term efficacy and safety data, including overall survival findings, with docetaxel, abiraterone, enzalutamide or apalutamide in combination with ADT for mHSPC
  • Clinical and biologic factors informing the selection of docetaxel, abiraterone, enzalutamide or apalutamide for men with mHSPC
  • Key efficacy and safety results from the Phase III PEACE-1 study of docetaxel with or without abiraterone with or without local radiation therapy for men with mHSPC
  • Findings from the Phase III ARASENS trial showing increased overall survival with darolutamide in combination with docetaxel and ADT for mHSPC
  • Strategies to overcome barriers to successful delivery of guideline-endorsed therapies in mHSPC

MODULE 3: Selection and Sequencing of Therapy for Metastatic CRPC (mCRPC) — Dr Antonarakis

  • Available results from the CARD study and other trials investigating the optimal sequencing of cabazitaxel for mCRPC
  • Recent studies attempting to define the role of secondary hormonal therapy in the management of mCRPC
  • Impact of the addition of bone-protecting agents to radium-223/enzalutamide in the Phase III EORTC-1333-GUCG/PEACE-3 trial; implications for practice and ongoing research
  • Prevalence of PSMA in prostate cancer and available testing methodologies to evaluate PSMA expression
  • Biologic rationale for targeting PSMA and mechanism of action of the novel radioligand therapy 177Lu-PSMA-617
  • Key efficacy and safety findings from the Phase III VISION study evaluating 177Lu-PSMA-617 for progressive, PSMA-positive mCRPC; FDA approval and role in clinical practice
  • Other novel agents and strategies (eg, cabozantinib, immune checkpoint inhibitors) under investigation for mCRPC

MODULE 4: Current and Future Integration of PARP Inhibitors in the Management of Prostate Cancer — Dr Saad

  • Indications for and practical implementation of genetic testing for patients with prostate cancer
  • Long-term efficacy and safety findings with olaparib and rucaparib monotherapy for mCRPC; FDA-approved indications and optimal integration into current management algorithms
  • Early-phase data with investigational PARP inhibitors (eg, talazoparib, niraparib) administered as monotherapy in mCRPC
  • Biologic basis for combining PARP inhibitors with androgen receptor-targeted therapies in prostate cancer
  • Recently presented efficacy and safety findings from the Phase III PROpel trial evaluating olaparib and abiraterone versus abiraterone alone as first-line therapy for patients with mCRPC with or without homologous recombination repair (HRR) gene mutations; implications for clinical management
  • Available data from the Phase III MAGNITUDE study of niraparib with abiraterone and prednisone as first-line therapy for patients with mCRPC with or without HRR gene alterations
  • Other ongoing Phase III clinical research efforts evaluating the role of PARP inhibitors with secondary hormonal agents for mCRPC (eg, TALAPRO-2, CASPAR) and mHSPC (eg, TALAPRO-3, AMPLITUDE)

Target Audience
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appraise published research findings and current guideline recommendations on optimal management approaches to biochemical recurrence after local treatment for prostate cancer, and counsel patients regarding the potential benefits of systemic therapy.
  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options with patients.
  • Explore available data with treatment intensification using cytotoxic and/or secondary hormonal therapy for metastatic hormone-sensitive prostate cancer, and effectively integrate these approaches into current clinical management algorithms.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with metastatic CRPC (mCRPC), considering age, comorbidities, prior therapeutic exposure and other relevant clinical and biologic factors.
  • Assess available research supporting the use of PARP inhibitors alone or with secondary hormonal therapies for patients with mCRPC, and discern how to optimally incorporate these agents into current and future treatment plans.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Concepcion has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Saad — Advisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme. Dr Smith — Advisory Committee, Consulting Agreements and Contracted Research: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc.

MODERATOR — Emmanuel S Antonarakis, MD – Advisory Committee: AIkido Pharma Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Bristol-Myers Squibb Company, Constellation Pharmaceuticals, Curium Pharma, Exact Sciences, Foundation Medicine, Invitae, Ismar Healthcare NV, Merck, Orion Corporation, Tempus; Consulting Agreements: EcoR1 Capital LLC, KeyQuest Health; Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Clovis Oncology; Other: QIAGEN: licenser of technology.

RESEARCH TO PRACTICE PRESIDENT NEIL LOVE, MD — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck, and Pfizer Inc.

New Orleans Ernest N Morial Convention Center
900 Convention Center Blvd
New Orleans, LA 70130
Phone: (504) 582-3000

Meeting Room
Rooms 265-268 (Second Floor)

Directions
The New Orleans Ernest N Morial Convention Center is the main venue for the American Urological Association (AUA) 2022 Annual Meeting.

 

Thank you for your interest in our CME program. At this time online preregistration is closed for in-person participants. SEATS ARE STILL AVAILABLE FOR THE SESSION. Our Onsite Registration Desk will be open at 7:15 AM Central Time on Friday, May 13th. If you are interested in attending, please visit our onsite registration desk located outside Meetings Rooms 265-268 (Second Floor) of the New Orleans Ernest N Morial Convention Center (900 Convention Center Blvd).

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

There is no fee for participation in this event.

Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.